New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:31 EDTAMRN, KERXKeryx slide attributable to Zerenex market exclusivity worries, The Street says
The 22% decline in Keryx Pharmaceuticals (KERX) seen on Friday was attributable to concerns raised by a report from IPD Analytics about the company's ability to gain FDA "New Chemical Entity" status for Zerenex, according to The Street's Adam Feuerstein. The author notes that Amarin (AMRN) shares are sometimes volatile over a similar concern, namely that a key drug may not be able to secure NCE status, which grants five years of market exclusivity for a unique pharmaceutical compound. Reference Link
News For KERX;AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
10:32 EDTAMRNAmarin management to meet with Oppenheimer
Meeting to be held in New York on May 27 hosted by Oppenheimer.
May 20, 2015
10:29 EDTKERXOptions with decreasing implied volatility
Options with decreasing implied volatility: ZIOP KING ARIA CTRP WTW VHC XON KERX VIPS JCP
10:16 EDTKERXHigh option volume stocks
Subscribe for More Information
May 19, 2015
11:59 EDTKERXOptions with decreasing implied volatilit
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use